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Objectives: This study aimed to demonstrate enhanced survival extrapolation methods using electronic health record-derived
real-world data (RWD).
Methods: The study population included patients diagnosed of ER1/HER22 metastatic breast cancer who started first-line
treatment with anastrozole or letrozole between November 18, 2014, and November 18, 2015. Two patient cohorts were
constructed: a clinical trial cohort from digitized MONARCH-3 clinical trial results and a RWD cohort from a deidentified
electronic health record-derived database. RWD patients were weighted to trial baseline covariate distributions. Standard
parametric approaches were applied to trial data and a “best-fit” model was selected. We demonstrate traditional and
enhanced hybrid (pooling with weighted RWD at start, 75%, or end of trial) extrapolation approaches.
Results: Observed and estimated 5-year progression-free survival (PFS) rates in extrapolating the trial control arm (n = 165)
were comparable across all methods. Compared with the observed 5-year mean PFS in the RWD cohort (n = 118) of 20.4
months (95% confidence interval [CI] 16.9-23.8), there was some variation among studied methods. Best-fit standard
parametric model (log-normal) had 5-year mean PFS of 21.3 months (95% CI 18.2-24.9), and for the hybrid methods in
order of estimate conservativeness was start of trial (20.8 months; 95% CI 18.5-23.2), 75% of trial (21.3 months; 95% CI
18.1-24.5), and end of trial (21.8 months; 95% CI 18.8-25.2).
Conclusions: Our study leverages RWD to enhance long-term survival extrapolation. Future use cases should include applying
patient eligibility criteria, weighting on baseline characteristics, and choice of time window to add RWD to trial data.
Keywords: cancer treatment, clinical trial, real-world data, survival extrapolation.
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A common problem for health technology appraisers of newer
oncology treatments is that the duration of follow-up in oncology
clinical trials is often much shorter than the expected survival of
patients. To address this issue, survival extrapolation methods are
commonly used to estimate life-years and quality-adjusted life-
years for economic analyses and health technology assessments
(HTAs).1 Extrapolations typically show expected outcomes for
years or even decades beyond trial time horizons, yet they vary
widely in terms of the assumptions and accuracy on the longer-
term survival outcomes. In response, HTA agencies such as the
National Institute for Health and Care Excellence have endorsed
published Decision Support Unit Technical Support Documents for
extrapolating survival from clinical trial data.2,3 Most recommend
incorporating real-word data (RWD), such as data from disease
registries, to validate the plausibility of extrapolations and better
inform long-term survival estimates. In recent years, clinical15 - see front matter Copyright ª 2021, ISPOR–The Professional Society for
cess article under the CC BY-NC-ND license (http://creativecommons.org/licdepth, recency, and long-term data availability have improved
with electronic health records (EHRs) of patients with cancer. The
use of EHR-derived RWD in HTA assessments can allow for se-
lection of real-world patients similar to those in the trial,
extending follow-up time, contextualizing results, and improving
evaluation of long-term outcomes observed in trial patients. In
addition to more precise matching of cohorts, having an EHR-
derived RWD with sufficient follow-up (for currently available
treatments) allows for the comparison of alternative methods for
extrapolating survival beyond the trial with observed outcomes
for real-world patients over an extended time horizon. It is
currently unknown how specific choices of matching and
extrapolation affect estimates of long-term survival.
To help fill this gap, the objective of this study was to enumerate
and demonstrate novel techniques for enhanced trial survival
extrapolation using long-term survival estimates from RWD. To
illustrate the opportunity, we used data from the control arm of a
large randomized clinical trial of patients with metastatic breastHealth Economics and Outcomes Research. Published by Elsevier Inc. This is an
enses/by-nc-nd/4.0/).
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fied using EHR-derived data.4 In the primary analysis, we used RWD
patients who were most similar to trial patients and focused on the
control arm only. The trade-offs between clinical specificity and
representativeness in identifying real-world comparator cohorts for
cost-effectiveness research have been discussed elsewhere.5
Methods
To demonstrate the application of enhanced hybrid extrapo-
lation methods, we conducted a case study using trial and RWD
patients with ER-positive HER2-negative (ER1/HER22) mBC who
started first-line treatment with anastrozole or letrozole.
Patient Population—Clinical Trial Cohort
The clinical trial patient cohorts used in this study were
reconstructed by digitizing published6 survival curves and reported
patient information available in the primary manuscripts from the
MONARCH-3 trial. Details on the study eligibility criteria have been
previously published,4 and a summary is provided in the Appendix
Note 1 in Supplemental Materials found at https://doi.org/10.1016/j.
jval.2021.08.013. In brief, MONARCH-3 is a double-blind, random-
ized phase III study of abemaciclib or placebo plus a nonsteroidal
aromatase inhibitor (AI) in 493 postmenopausal women with ER1/
HER22 mBC who had no previous systemic therapy in the
advanced setting. Only trial patients who received the placebo
treatment of AI only are used in this analysis (n = 165).
Patient Population—Real-World Cohort
Data source
The RWD cohort was constructed using data from the Flatiron
Health database, a US nationwide longitudinal, deidentified
database derived from EHR data containing patient-level struc-
tured and unstructured data curated via technology-enabled
abstraction.6-8 By the end of the observation period used for this
analysis (January 31, 2020), the database comprised more than
280 cancer clinics (w800 sites of care). An institutional review
board approval of the study protocol was obtained before study
conduct and included a waiver of informed consent.
A real-world patient cohort was selected according to trial-
specific inclusion and exclusion criteria and trial-specific enroll-
ment windows (Appendix Note 1 and Appendix Table 1 in Sup-
plemental Materials found at https://doi.org/10.1016/j.jval.2021.
08.013) for the MONARCH-3 trial of patients with mBC.4 In brief,
adult female patients with ER1/HER22 mBC were included if
their treatment with either anastrozole or letrozole as first-line
treatment initiated any time from November 18, 2014, to
November 18, 2015, confirmed in unstructured information. Using
MONARCH-3 trial inclusion/exclusion criteria, patients were
excluded from the analysis if they had an Eastern Cooperative
Oncology Group Performance Status of .1; had inadequate organ
function; had evidence or history of central nervous system me-
tastases; received a previous treatment with systemic chemo-
therapy for advanced disease, everolimus, or a cyclin-dependent
kinase 4 and 6 inhibitor (ie, palbociclib, ribociclib, or abemaciclib);
or were currently receiving an investigational drug in a clinical
trial during the trial enrollment window (Fig. 1). Patients with
missing or not documented organ function and functional status
were included in the primary analysis.
Baseline characteristics weighting for RWD cohort
To improve the balance in patient characteristics between co-
horts, patients in the RWD cohort were weighted on baselinecharacteristics to reflect the distribution of baseline characteristics
of trial patients. We adopted an approach analogous to propensity
score modeling that weights RWD patients to achieve cohort-level
balance for all measured baseline characteristics.9 Weights were
estimated using the generalized method of moments estimator on
trial reported moments (ie, means or proportions of variables).10-
12 Patients in the RWD cohort were weighted on trial median age
(#63 vs.63 years), race (white, other), number of metastatic sites
at index date (1, 2, $3), site of metastasis (bone only, other),
progesterone receptor status (positive, negative/missing), and use
of AI (letrozole, anastrozole).
We also performed an exploratory analysis using 3 additional
RWD cohorts with less restricted criteria, including no baseline
characteristics weighting, no treatment window restriction, and
less trial selection criteria.
Follow-up and outcomes
The length of possible follow-up time for each patient was
defined as the difference in months between the start date of first-
line therapy and the end date of the clinical trial or the most
recent EHR activity date (clinic visit, drug administration, or ex-
pected end date of most recent oral therapy). The primary
outcome for comparison in this study was the mean progression-
free survival (PFS) time and PFS rate (%) at 5 years from the start
date of first-line treatment. For RWD patients, the real-world PFS
(rwPFS) event was disease progression or death, which was based
on a clinician-anchored documentation of disease, an approach
that has been shown to be scalable, reliable, and meaningful and
may provide more context into real-world outcomes measures
than response rates.13,14 The 5-year PFS rate for clinical trial pa-
tients was extrapolated from trial outcomes whereas for real-
world patients the 5-year rwPFS rate was observed and did not
require extrapolation.
Statistical Analysis
We used the clinical trial and RWD cohorts to demonstrate
approaches for enhanced extrapolation of patient outcomes
combining information from a clinical trial with information from
RWD patients and compared results with observed long-term
outcomes in RWD (reference; approach 0) and a standard
approach for extrapolation using only the clinical trial (approach
1). The 3 approaches for enhanced extrapolation used data from
trial pooled with RWD data since index date (approach 2), trial
with RWD added at the end of trial (approach 3), and trial with
RWD added beyond the point of 75% trial follow-up completion
(approach 4). Each extrapolation approach 1 to 4 is detailed below
and summarized in Table 1. Potential systematic differences be-
tween extrapolated outcomes were assessed quantitatively and
qualitatively from mean survival and survival rates at the end of
real-world follow-up time and visual inspection of survival curves.
Standard trial extrapolation approach (approach 1)
Standard parametric models were fitted to the clinical trial
data to extrapolate the outcomes.1 The models included expo-
nential, Weibull, Gompertz, log-logistic, log-normal, generalized
Gamma, and generalized F distributions. Visual inspection, sta-
tistical tests including Akaike information criterion (AIC) and
Bayesian information criterion (BIC), and plausibility of survival
estimates were used to assess the goodness of fit of parametric
distributions. Visual inspection helps to narrow the review of
possible survival curves by eliminating those that are clearly not
good fits. Statistical tests, in the order of smallest BIC and then
smallest AIC, further refine the selection. The plausibility of sur-
vival estimates beyond trial follow-up period is the final criterion
Figure 1. Cohort selection diagram for real-world study population.





Step 2: Adult patients who are HR+/HER2– and receiving AI (Ietrozole or anastrozole monotherapy) or Abemaciclib as 1L therapy:
Step 3: Exclude patients who received prior (neo)adjuvant endocrine therapy including anastrozole, letrozole, exemestane, tamoxifen:
Step 4: Excluding patients with prior treatment with any CDK4/6 inhibitor (i.e, palbociclib, ribociclib, abemaciclib):
Step 5: Excluding patients with prior treatment with everolimus:
n = 2343
Step 6: Excluding patients with ECOG > 1:
n = 2091




Step 9: Excluding patients with history of HIV:
Step 8: Excluding patients with CNS mets:
Step 10: Excluding patients with history of hepatitis B and/or C:
n = 1062
n = 207
Step 11: Treatment start before November 11, 2015 and after 2014-11-18:
1L indicates first-line; AI, aromatase inhibitor; CDK, cyclin-dependent kinase; CNS, central nervous system; ECOG, Eastern Cooperative Oncology Group; HIV,
human immunodeficiency virus; mets, metastases.
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appropriate comparator with sufficient follow-up. For example,
we considered that it is unlikely that the 5-year PFS rate is ,5%
among patients with HR1/HER22 mBC. The estimated median
survival time-to-event (PFS) from parametric models were also
compared with the corresponding trial observed median survival
times, if observed. A “best-fit” model was selected based on the
criteria and was used to extrapolate longer-term outcomes from
the fitted parametric models.
Enhanced methodological approaches (approaches
2-4)
To illustrate approaches for incorporating RWD into long-term
survival extrapolation from trial data, we proposed a 2-stage
enhanced method by including RWD patients during and
beyond the trial time horizon. Parametric distributions selected as
the “best-fit” model for trial patients were used for all survival
extrapolations, adjusting for the source of patient cohorts (clinical
trial vs RWD).Trial data pooled with RWD since index date (approach
2). This method fits parametric models, using combined sur-
vival data from both trials and RWD from the start of treatment to
the end of RWD long-term follow-up (January 31, 2020), adjusting
for patient cohorts (clinical trial vs RWD). All trial and RWD
patients were included in this analysis with the same entry at
the index date (e.g., start of treatment) in this study.
Trial with RWD added at the end of trial (Approach
3). It is common that survival extrapolation was only per-
formed from the end-of-trial follow-up, which sometimes
included only a small number of patients.15 Therefore, we
evaluated whether adding additional RWD patients to this group
of patients would help improve survival extrapolation. This
method fits parametric models in 2 periods: (1) short-term
survival estimates are generated using trial data until the end-
of-trial follow-up duration, and (2) long-term survival estimates
are generated by adding RWD patients with a duration of
follow-up that met or exceeded that of the trial patients (see
Table 1. Approaches for extrapolation of patient outcomes.
Approaches* Data sources used Follow-up duration, months Demonstration number
Traditional extrapolation Clinical trial 31 1
Enhanced with RWD added at 0% (trial start) Clinical trial 1 RWD 60 2
Enhanced with RWD added at 100% (trial end) Clinical trial 1 RWD 60 3
Enhanced with RWD added at 75% (during trial) Clinical trial 1 RWD 60 4
RWD indicates real-world data.
*All enhanced approaches used the same parametric model as the traditional extrapolation approach.
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org/10.1016/j.jval.2021.08.013). The included RWD patients had
delayed entry at the end of trial.
Trial with RWD added at 75% trial follow-up completion
(Approach 4). Due to the large amount of patients censored at
the end of a trial, evidence review groups have proposed to
extrapolate survival estimates at an earlier time (eg, 0%-30%)
during the trial follow-up.16 Given that we did not have
individual-level data from trial patients, 75% trial completion was
considered the closest scenario, based on the risk table published
from the MONARCH-3 trial. This method fits parametric models in
2 periods: first, short-term survival estimates are generated using
trial data only up until 75% of patients have observed events or
were censored, and second, long-term survival estimates are
generated by combining the remaining 25% of trial patient and
RWD patients with follow-up duration beyond the cutoff time
for 75% trial completion (see Appendix Table 2 in Supplemental
Materials found at https://doi.org/10.1016/j.jval.2021.08.013). In
the analysis, trial patients were included for their full follow-up
time regardless of cutoff time, and RWD patients were included
if they had outcomes or were censored after the cutoff time
with a delayed entry at the cutoff time.
In the primary analysis for both end-of-trial and 75% comple-
tion methods, the duration of trial follow-up (months) was used to
decide the cutoff time. Sensitivity analysis was conducted using
the exact trial end date as the cutoff time. To check whether
survival outcomes between trial and RWD cohorts were similar,
we applied the same parametric model selection process to the
RWD cohort in sensitivity analysis. We further tested the differ-
ences in PFS between trial and RWD cohort under the “best-fit”
baseline hazard function in the pooled method. In addition, we
performed exploratory extrapolation analysis using 30-year as a
proxy of lifetime time horizon across all approaches.
All analyses are conducted using R version 3.6.1.Results
Study Cohorts
The digitized trial data represented the experience of 165 pa-
tients with mBC who received first-line AI in MONARCH-3. Among
the 18 110 patients with mBC in the real-world database, 1 062
patients met the inclusion and exclusion criteria and received AI as
the first-line treatment. After further restriction to the same
enrollment window as the trial, the RWD cohort included 207 pa-
tients with mBC (Fig. 1). After weighting on baseline characteristics
of the RWD cohort to match the trial cohort, the effective sample
size of the RWD cohort was 118 patients (Table 2). In brief,
compared with the trial patients, RWD patients who met the
selection criteria were more likely to be older, be white, have bone-only metastasis, have lower number of metastases, and receive
letrozole. Balance in the distributions of baseline characteristics was
achieved in most characteristics after weighting with the exception
of the number of metastatic sites and visceral metastatic involve-
ment. The mean 5-year PFS for the long-term RWD cohort
(approach 0; reference) was 20.4 months (95% CI 16.9-23.8), and
the observed 5-year PFS rate was 11.0% (95% CI 6.1-19.8; Table 3).
Standard Trial Extrapolation (Approach 1)
In mBC using approach 1, the log-normal distribution was
selectedas the “best-fit” forMONARCH-3patientswhoreceivedanAI
(model performance summarized in Appendix Fig. 1 and Appendix
Table 3 in Supplemental Materials found at https://doi.org/10.1016/
j.jval.2021.08.013). Using log-normal distribution in parametric
modeling, the approach 1 model estimated median PFS for patients
in the trial was 14.1 months (95% confidence interval [CI] 11.5-17.3),
comparedwith the trial reportedmedian PFS of 14.8months (95% CI
11.7-19.2). Themean5-year PFS for trial cohort (approach1)was 21.3
months (95% CI 18.2-24.9), using MONARCH-3 trial extrapolation
only with log-normal distribution (Table 3 and Fig. 2A). The 5-year
PFS rate extrapolated from the trial data was 11.0%, the same as the
observed 5-year PFS rate from long-term RWD.
Hybrid Methodological Approaches (Approaches 2-4)
RWD-enhanced survival extrapolation results from hybrid
methods approaches 2 to 4 are reported in Table 3 and Figure 2B
to D. Among the 3 hybrid methods, the mean 5-year PFS estimates
from the approach 2 pooled method were the lowest and had the
narrowest uncertainty (mean PFS 20.8 months; 95% CI 18.5-23.2),
followed by the estimates from approach 4 adding RWD at 75% of
trial follow-up completion (mean PFS 21.3 months; 95% CI 18.1-
24.5). The approach 3 method with RWD added at the end of trial
had the highest estimates for mean PFS at 21.8 months (95% CI
18.8-25.2). The approach 3 hybrid method with RWD added at the
end of trial had the highest 5-year PFS rate at 12.0% (95% CI 7.2-
17.2) compared with the other 2 hybrid methods. Visual inspec-
tion suggested that there might be discrepancy between the
parametric model using log-normal distribution and the Kaplan-
Meier survival curves for pooled and end-of-trial methods, but
not for 75% hybrid (Fig. 2). In particular, the number of patients at
risk dropped significantly for the end-of-trial method, which may
partially explain the observed discrepancy.
In the sensitivity analysis, we applied the same parametric
model selection process using the RWD patients only and found
that log-normal distribution was also selected as the “best-fit”
model for the RWD cohort. In addition, we did not observe a
statistically significant difference of PFS between the trial and
RWD patients under log-normal baseline hazards (P=.74). Using 30
years as a proxy for a lifetime time horizon, we found that
extrapolation from trial alone resulted in a slightly higher estimate
of the mean lifetime PFS (27.8 months) than extrapolation from
Table 2. Baseline characteristics of patients in real-world cohort












Age (years, by trial median age), %
#63 24 50 50
.63 76 50 50
Race, %
White 75 62 62
Other 25 38 38
PR status, %
Positive 76 77 77
Negative 24 23 22
Site of metastasis, %
Bone only 43 24 24
Visceral 23 35 76
Number of metastasis, %
1 57 29 28
2 19 26 26
$3 9 18 46
AI, %
Letrozole 46 79 79
Anastrozole 54 21 21
AI indicates aromatase inhibitor; I/E, inclusion/exclusion; PR, progesterone
receptor; RWD, real-world data.
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hybrid methods, where the pooled methods had the lowest esti-
mate (26.8 months) compared with end-of-trial and 75% hybrid
with the narrowest 95% CI (see Appendix Table 4 in Supplemental
Materials found at https://doi.org/10.1016/j.jval.2021.08.013).Discussion
In this study, we demonstrated the potential for pooling in-
formation from clinical trial patient cohorts with RWD cohorts to
enhance survival extrapolation with longer follow-up time. The
clinical depth, real-world endpoints, and longitudinality of EHR-
derived RWD facilitated matching and weighting of patient pop-
ulations in the 3 hybrid approaches illustrated here. Among the
enhanced survival extrapolation methods explored, we found that
outcomes were similar between the clinical trial and selected
RWD cohort with rigorous application of patient eligibility criteria,
weighting, and choice of time window. Among the 3 hybrid
methods, the pooled method with full follow-up time from both
cohorts provided a weighted 5-year mean PFS in between the trial
and RWD cohort-specific estimates, with a narrower 95% CIs from
larger sample size.
The variations in PFS estimates were because of different
contributions from short-term and long-term survivors and un-
derlying assumptions. Although both end-of-trial and 75%
completion methods only assume that long-term survival after a
certain cutoff point follows the same distribution, regardless of
short-term survival outcomes, the pooled method assumes that
both short-term and long-term survival outcomes among trial and
RWD patients follow the same distributions of hazards. There is
also a trade-off between sample size and conservativeness of es-
timations dependent on the absolute and relative number of RWD
patients included in the analysis with trial patients. As was shown
in our analysis, including all RWD patients in the pooled analysisyielded a larger sample size and provided an estimation with the
narrowest CI compared with other hybrid methods. Moreover,
qualitative evaluation such as visual inspection can be helpful in
evaluating different approaches and their assumptions. The
Kaplan-Meier curve showed a larger dip for the end-of-trial
method. This dip was possibly due to the small number of pa-
tients at risk toward the end of the trial, which could have an
influential impact on survival extrapolation. This observed
discrepancy between the Kaplan-Meier curve and the parametric
model suggested that the end-of-trial method (Fig. 2C) is rela-
tively an unpreferred approach given the unstable estimates to-
ward the end of trial. Other factors, such as the completeness of
trial survival outcomes and length of the trial compared with the
natural history of the disease in the patient population, may also
be considered for comparing different approaches.
We selected a RWD cohort that closely matched the clinical trial
eligibility criteria, weighted by baseline characteristics, and
restricted to a similar treatment initiation time window. It is
possible that matching to the trial I/E criteria is not required when
the objective is not emulating the clinical trial or the purpose is
intended to be more generalizable. The details of selecting a real-
world comparator group that is relevant to the research question
have been previously discussed.5 In our exploratory analysis, we
found that all 3 RWD cohorts with less restricted selection criteria
had larger sample size (see Appendix Table 5 and Appendix Figure 2
in Supplemental Materials found at https://doi.org/10.1016/j.jval.2
021.08.013). Relaxed RWD cohorts also had longer median rwPFS
than the primary RWD cohort as expected, because patients in the
RWD cohorts were more likely to be white and less likely to have
.1 site of metastasis (Table 3). Given that the focus of this study is
to demonstrate the opportunity to enhance trial survival extrapo-
lation with external RWD, we selected the restricted RWD cohort
that had the most similar survival patterns, with the trade-off of a
smaller sample size and shorter follow-up. In addition, we only
demonstrated the selection of standard parametric models using
trial data in the primary analysis. Nevertheless, it is possible to
reselect the “best-fit” model using information from both trial and
RWD cohorts. In our exploratory analysis of refitting the standard
parametric models, survival curves of log-normal distribution and
AIC/BIC showed that it fitted the combined data well in both pooled
and 75% methods, but not in “end-of-trial” approach (see Appendix
Fig. 3 in Supplemental Materials found at https://doi.org/10.1016/j.
jval.2021.08.013). In the visual exploration of the hazard functions
from all cohorts, we have found that both RWD only and all com-
bined cohorts met the hazards assumption of log-normal distribu-
tion (increases over time from 0 to reach a maximum and then
decreases monotonically), whereas there was an upward increase at
around month 20 in the trial cohort, possibly due to small number
of patients in the risk set (see Appendix Fig. 4 in Supplemental
Materials found at https://doi.org/10.1016/j.jval.2021.08.013). Our
further exploration using flexible spline-based models (1-5 knots
under either proportional hazards or proportional odds assump-
tion) did not yield better fitted hazards or survival curves than log-
normal distribution (see Appendix Figs. 5 and 6 in Supplemental
Materials found at https://doi.org/10.1016/j.jval.2021.08.013).17,18
These exploratory findings suggest visual inspection and addi-
tional expert clinical opinions might be needed.
To the best of our knowledge, this is the first study illustrating
different approaches incorporating external real-world EHR-
derived data to enhance survival extrapolation from a clinical trial
to reduce uncertainty. By using high-quality EHR data, we were
able to select RWD patients who were comparable with trial pa-
tients based on demographic and clinical characteristics. We
further balanced the baseline characteristics between the trial and
RWD patient cohorts using propensity score weighting. Clinical
Table 3. Five-year PFS and survival rates, estimated by standard trial extrapolation and RWD-enhanced methods.



















RWD added at 75%
trial completion
Total number of patients 207 165 371 217 234
Effective number of patients 118 165 207 186 197
Mean PFS, months 20.4 (16.9-23.8) 21.3 (18.2-24.9) 20.8 (18.5-23.2) 21.8 (18.8-25.2) 21.3 (18.1-24.5)
Mean PFS rate at 5-years 11.0% (6.1-19.8) 11.0% (6.4-16.5) 10.4% (7.2-13.9) 12.0% (7.2-17.2) 11.1% (7.2-16.4)
Note. Mean survival times were estimated at the end of RWD follow-up: 61 months for mBC.
mBC indicates metastatic breast cancer; PFS, progression-free survival; RWD, real-world data.
6 VALUE IN HEALTH - 2021trials such as the MONARCH-3 study that only report PFS and have
limited follow-up are vulnerable to bias in extrapolating mean
survival.14 Nevertheless, RWD can observe long-term outcomes.Figure 2. Survival curves of log-normal distribution extrapolation of
methods. (A) Trial-only extrapolation (approach 1). (B) Pooled trial1 RW
extrapolation (approach 3). (D) Hybrid trial 1 RWD (at 24 months of t
gray band represents the 95% confidence interval of progression-free
165 94 58 3 0 0 0
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mBC indicates metastatic breast cancer; RWD, real-world data.Our sensitivity analysis on overall survival extrapolation using
RWD patients with short-term follow-up as a proxy of immature
trial data suggested potential bias to overestimate long-termprogression-free survival among patients with mBC by different
D extrapolation (approach 2). (C) Hybrid trial1 RWD (end-of-trial)
rial, ie, 75% of trial completion) extrapolation (approach 4). Note:
survival estimates using log-normal distribution.
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-- 7overall survival compared with RWD patients with full long-term
follow-up. In such circumstances where trial data are immature, it
might be more important to incorporate survival information from
a comparable RWD cohort with sufficient follow-up to improve
long-term survival estimates. Furthermore, the proposed hybrid
approaches allow flexibility for adding RWD patients at various
time points, with the trade-off between analytical sample size and
survival estimation.
There are also limitations. Our case study was limited to the
control arm in the MONARCH-3 study and did not estimate the
treatment effects between experimental and control treatments.
This was due to the consideration that long-term follow-up of a
new treatment is less likely to be available among RWD patients at
the time of HTA appraisal submission. In this case, future analysis
using trial-only extrapolation of experimental treatment and
enhanced trial-RWD extrapolation of placebo treatment may be an
option to estimate treatment effects. If long-term follow-up of a
new treatment is available among RWD patients, proposed hybrid
methods can be applied to both treatment arms for treatment effect
estimation. In addition, we were not able to look into several as-
pects because of the lack of individual-level data from the trial
patients. We selected the cutoff time point (0%-100% trial comple-
tion) in the enhanced hybrid approach arbitrarily, which may have
an impact on the survival estimation. If individual-level data of trial
patients are available in other use cases, censoring patterns should
be considered in choosing a more informed cutoff time point. The
trial cohort had a dip in survival probability around month 27. This
sudden change in survival could be due to the small number of
patients left in the trial (n = 7 at month 21), but patient-level
censoring data are needed for further investigation. It is also un-
clear whether the pivot in the hazards function among trial patients
was due to censoring or biological toxicity. Given that it was not
observed in the RWD data, we choose to use the log-normal dis-
tribution as the best fitted model. More informed model choices,
especially if complex models are needed, may be able to be made
with more detailed patient-level data, clinical expert opinions, or
other external data sources. Moreover, EHR-derived RWD is limited
to information documented during the course of routine care, and
therefore, it may not capture all relevant information. Real-world
treatment and progression were retrospectively captured from
EHR using a clinician-anchored abstraction approach. Although
previous studies have shown the consistency between the real-
world progression variable with progression published in clinical
trials,14,19 there is potential misclassification in both treatment lines
and real-world outcome variables. RWD used in our case study is
United States based, which may not be generalizable to patient
experiences outside of the United States. Nevertheless, it is possible
to select a US patient cohort that has similar baseline characteristics
and treatment as a non-US patient population. We were only able
to compare the extrapolated survival estimates with the observed
PFS in the same RWD cohort, given that PFS is not available in
commonly used external databases. It will be helpful to evaluate
the robustness of the approaches using other external data sources
if possible. Finally, the usability of this enhanced approach,
including inclusion criteria and characteristic weighting, may vary
by specific use cases across different tumor types with different
treatment patterns and survival trajectories.Conclusions
Our case study demonstrated the strengths and limitations of
several methods to enhance survival extrapolation by adding
additional information from external RWD patients. We have also
shown great potential in leveraging RWD with clinical depth andlongitudinality. Further EHR-based studies using RWD are needed
to confirm our findings and to extend beyond this use case for
other cancer types and antineoplastic therapies.Supplemental Material
Supplementary data associated with this article can be found in the
online version at https://doi.org/10.1016/j.jval.2021.08.013.Article and Author Information
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